Comparison of prostate cancer detection rates between magnetic resonance imaging-targeted biopsy and transrectal ultrasound-guided biopsy according to Prostate Imaging Reporting and Data System in patients with PSA ≥4 ng/mL: a systematic review and meta-analysis.

Journal: Translational andrology and urology
Published Date: Dec 1, 2019

Abstract

BACKGROUND: Previous studies have investigated magnetic resonance imaging-targeted biopsy (MRI-TBx) on the detection for prostate cancer (PCa). Prostate Imaging Reporting and Data System (PI-RADS), as a standardized MRI reporting system, has widely been used in the management of PCa. However, basing the PI-RADS score, the comparability between MRI-TBx and transrectal ultrasound-guided biopsy (TRUS-Bx) in diagnosing PCa remained inconsistent or even controversial. Thus, this systematic meta-analysis aimed to assess the value of PI-RADS in sifting better prostate biopsy method.

Authors

  • Kai Zhu
    Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
  • Zhiqiang Qin
    Department of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
  • Jianxin Xue
    Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
  • Chenkui Miao
    Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
  • Ye Tian
    State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics and Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China.
  • Shouyong Liu
    Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
  • Shenhao Zhu
    Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
  • Qi Gu
    Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
  • Chao Hou
    Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
  • Aiming Xu
    Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
  • Jie Yang
    Key Laboratory of Development and Maternal and Child Diseases of Sichuan Province, Department of Pediatrics, Sichuan University, Chengdu, China.
  • Zengjun Wang
    Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals